Latest & greatest articles for adverse events

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adverse events or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adverse events and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adverse events

1. Benchmarking study helps hospitals improve measurement of adverse events

Benchmarking study helps hospitals improve measurement of adverse events Signal - Benchmarking study helps hospitals improve measurement of adverse events Dissemination Centre Discover Portal NIHR DC Discover Benchmarking study helps hospitals improve measurement of adverse events Published on 20 June 2017 One in ten inpatients in Welsh hospitals experienced an adverse event of some sort, about half of which were potentially preventable. This is very similar to the rate in other countries (...) understand how many events were preventable and the degree of harm. The two-step process found 10.3% of patients had an adverse event, while the tool found 8% adverse events. Hospitals which carried out more surgery had higher rates of adverse events. Use of this trigger tool has since been dropped in Wales and a new “hybrid” system of adverse event identification is being developed. Share your views on the research. Why was this study needed? Global estimates of rates of adverse events range from about

NIHR Dissemination Centre2019

2. Infants anaesthetised without placing a tube in the trachea have fewer adverse breathing events

Infants anaesthetised without placing a tube in the trachea have fewer adverse breathing events Signal - Infants anaesthetised without placing a tube in the trachea have fewer adverse breathing events Dissemination Centre Discover Portal NIHR DC Discover Infants anaesthetised without placing a tube in the trachea have fewer adverse breathing events Published on 11 July 2017 Adverse breathing events are about three times more common when using endotracheal tubes than laryngeal mask airways (...) fewer airway-related complications than tubes. This Australian randomised controlled trial supported this, finding an adverse event rate of 53% with endotracheal tubes compared with only 18% with laryngeal mask airways. Conventional anaesthesia teaching advises the use of endotracheal tubes in infants even for relatively minor surgery, to provide a secure airway, but incidents may be more common when placing or removing the tube than a laryngeal mask. Share your views on the research. Why

NIHR Dissemination Centre2019

3. Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase

Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase Dissemination Centre Discover Portal NIHR DC Discover Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase Published on 26 June 2018 doi: In people with some types of severe, drug-resistant epilepsy, adding cannabidiol (...) ; three trials, 306 participants). The likelihood of reducing seizure frequency by 50% or more was moderately increased (43.5% with cannabidiol vs 25.0% with placebo; RR 1.74, 95% CI 1.24 to 2.43; two trials, 291 participants). Parents or carers reported an improvement in their child’s overall quality of life (59.8% with cannabidiol vs 34.5% with placebo; RR 1.73, 95% CI 1.33 to 2.26, two trials, 274 participants). Any adverse events (88.4% with cannabidiol vs 69.7% with placebo; RR 1.24, 95% CI 1.13

NIHR Dissemination Centre2019

4. Adverse events in people taking macrolide antibiotics versus placebo for any indication.

Adverse events in people taking macrolide antibiotics versus placebo for any indication. BACKGROUND: Macrolide antibiotics (macrolides) are among the most commonly prescribed antibiotics worldwide and are used for a wide range of infections. However, macrolides also expose people to the risk of adverse events. The current understanding of adverse events is mostly derived from observational studies, which are subject to bias because it is hard to distinguish events caused by antibiotics from (...) events caused by the diseases being treated. Because adverse events are treatment-specific, rather than disease-specific, it is possible to increase the number of adverse events available for analysis by combining randomised controlled trials (RCTs) of the same treatment across different diseases. OBJECTIVES: To quantify the incidences of reported adverse events in people taking macrolide antibiotics compared to placebo for any indication. SEARCH METHODS: We searched the Cochrane Central Register

Cochrane2019

5. Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial.

Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial. Importance: Despite guideline recommendations, many patients discontinue P2Y12 inhibitor therapy earlier than the recommended 1 year after myocardial infarction (MI), and higher-potency P2Y12 inhibitors are underutilized. Cost is frequently cited as an explanation for both of these observations. Objective (...) : To determine whether removing co-payment barriers increases P2Y12 inhibitor persistence and lowers risk of major adverse cardiovascular events (MACE). Design, Setting, and Participants: Cluster randomized clinical trial among 301 hospitals enrolling adult patients with acute MI (June 5, 2015, through September 30, 2016); patients were followed up for 1 year after discharge (final date of follow-up was October 23, 2017), with blinded adjudication of MACE; choice of P2Y12 inhibitor was per clinician

JAMA2019

6. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association

Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association | Arteriosclerosis, Thrombosis, and Vascular Biology Search Hello Guest! Login to your account Email Password Keep me logged in Search Archive of all online content January 1, 1981 - January 1, 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use (...) of cookies. Free Access article Jump to Free Access article Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association , MD, FAHA, Chair , FRCPath, PhD , MD, PhD, FAHA , MD, FAHA, Vice Chair , PharmD, MSPH, FAHA , MD, FAHA , MD , MD, FAHA , MD, FAHA , MD, MPH, FAHA , MD, FAHA , MD, FAHA , MD , PhD, FAHA , MD, PhD, FAHA Connie B. Newman , David Preiss , Jonathan A. Tobert , Terry A. Jacobson , Robert L. Page, II , Larry B. Goldstein , Clifford Chin , Lisa R

American Gastroenterological Association Institute2019

7. Major Adverse Cardiac Events and Mortality Associated with Electroconvulsive Therapy: A Systematic Review and Meta-analysis

Major Adverse Cardiac Events and Mortality Associated with Electroconvulsive Therapy: A Systematic Review and Meta-analysis 30557212 2018 12 20 1528-1175 130 1 2019 Jan Anesthesiology Anesthesiology Major Adverse Cardiac Events and Mortality Associated with Electroconvulsive Therapy: A Systematic Review and Meta-analysis. 83-91 10.1097/ALN.0000000000002488 WHAT THIS ARTICLE TELLS US THAT IS NEW: BACKGROUND:: Cardiac events after electroconvulsive therapy have been reported sporadically (...) , but a systematic assessment of the risk is missing. The goal of this study was to obtain a robust estimate of the incidence of major adverse cardiac events in adult patients undergoing electroconvulsive therapy. Systematic review and meta-analysis of studies that investigated electroconvulsive therapy and reported major adverse cardiac events and/or mortality. Endpoints were incidence rates of major adverse cardiac events, including myocardial infarction, arrhythmia, pulmonary edema, pulmonary embolism, acute

EvidenceUpdates2019

8. Inhaled steroids with and without regular salmeterol for asthma: serious adverse events.

Inhaled steroids with and without regular salmeterol for asthma: serious adverse events. BACKGROUND: Epidemiological evidence has suggested a link between use of beta₂-agonists and increased asthma mortality. Much debate has surrounded possible causal links for this association, and whether regular (daily) long-acting beta₂-agonists (LABAs) are safe, particularly when used in combination with inhaled corticosteroids (ICSs). This is an update of a Cochrane Review that now includes data from two (...) large trials including 11,679 adults and 6208 children; both were mandated by the US Food and Drug Administration (FDA). OBJECTIVES: To assess risks of mortality and non-fatal serious adverse events (SAEs) in trials that randomised participants with chronic asthma to regular salmeterol and ICS versus the same dose of ICS. SEARCH METHODS: We identified randomised trials using the Cochrane Airways Group Specialised Register of trials. We checked websites of clinical trials registers for unpublished

Cochrane2018

9. In-hospital versus postdischarge major adverse events within 30 days following lower extremity revascularization

In-hospital versus postdischarge major adverse events within 30 days following lower extremity revascularization 30301689 2018 11 11 1097-6809 2018 Oct 06 Journal of vascular surgery J. Vasc. Surg. In-hospital versus postdischarge major adverse events within 30 days following lower extremity revascularization. S0741-5214(18)31793-2 10.1016/j.jvs.2018.06.207 Studies using hospital discharge data likely underestimate postoperative morbidity and mortality after lower extremity revascularization (...) because they fail to capture postdischarge events. However, the degree of underestimation and the timing of postdischarge complications are not well-characterized. We used the American College of Surgeons National Surgical Quality Improvement Program procedure-targeted vascular databases from 2011 to 2015 to tabulate 30-day adverse events (in hospital and after discharge) for lower extremity bypass (LEB) and percutaneous vascular interventions (PVIs) performed for claudication and chronic limb

EvidenceUpdates2018

10. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. OBJECTIVE: To assess the association between the use of sodium glucose cotransporter 2 (SGLT2) inhibitors and seven serious adverse events of current concern. DESIGN: Register based cohort study. SETTING: Sweden and Denmark from July 2013 to December 2016. PARTICIPANTS: A propensity score matched cohort of 17 213 new users of SGLT2 inhibitors (dapagliflozin, 61%; empagliflozin (...) , 0.71 to 1.38) or acute pancreatitis (1.3 v 1.2, 1.16, 0.64 to 2.12). CONCLUSIONS: In this analysis of nationwide registers from two countries, use of SGLT2 inhibitors, as compared with GLP1 receptor agonists, was associated with an increased risk of lower limb amputation and diabetic ketoacidosis, but not with other serious adverse events of current concern. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http

BMJ2018 Full Text: Link to full Text with Trip Pro

11. What Is the Diagnostic Accuracy of Cardiac Biomarkers for the Prediction of Adverse Cardiac Events in Patients Presenting With Acute Syncope?

What Is the Diagnostic Accuracy of Cardiac Biomarkers for the Prediction of Adverse Cardiac Events in Patients Presenting With Acute Syncope? Annals of Emergency Medicine Email/Username: Password: Remember me Search Terms Search within Search Share this page Copyright © 2018 Inc. All rights reserved. | | | | | | The content on this site is intended for health professionals. We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree

Annals of Emergency Medicine Systematic Review Snapshots2018

12. Combination of the CYP2C19 metabolizer and the GRACE risk score better predicts the long-term major adverse cardiac events in acute coronary syndrome undergoing percutaneous coronary intervention

Combination of the CYP2C19 metabolizer and the GRACE risk score better predicts the long-term major adverse cardiac events in acute coronary syndrome undergoing percutaneous coronary intervention 30193195 2018 10 30 1879-2472 170 2018 10 Thrombosis research Thromb. Res. Combination of the CYP2C19 metabolizer and the GRACE risk score better predicts the long-term major adverse cardiac events in acute coronary syndrome undergoing percutaneous coronary intervention. 142-147 S0049-3848(18)30476-6 (...) 10.1016/j.thromres.2018.08.016 Both Global Registry of Acute Coronary Events (GRACE) risk score and CYP2C19 metabolizer status can independently predict major adverse cardiac events (MACEs) in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). We investigated whether their combination could better predict MACE occurrence in patients with ACS undergoing PCI. This retrospective cohort study included 548 consecutive patients with ACS undergoing PCI. A

EvidenceUpdates2018

14. Prospective Validation of Clinical Criteria to Identify Emergency Department Patients at High Risk for Adverse Drug Events

Prospective Validation of Clinical Criteria to Identify Emergency Department Patients at High Risk for Adverse Drug Events 29517818 2018 09 11 1553-2712 25 9 2018 Sep Academic emergency medicine : official journal of the Society for Academic Emergency Medicine Acad Emerg Med Prospective Validation of Clinical Criteria to Identify Emergency Department Patients at High Risk for Adverse Drug Events. 1015-1026 10.1111/acem.13407 Adverse drug events (ADEs) cause or contribute to one in nine (...) tertiary and one community hospital in Canada. We enrolled 1,529 adults presenting to EDs over 12 months. We applied two clinical decision rules and collected baseline variables prior to assessments by clinical pharmacists and physicians. We compared the physician and pharmacist diagnoses with the decision rule results. The primary outcome was a moderate or severe ADE, defined as an unintended and harmful event related to medication use or misuse, which required a change in medical therapy, diagnostic

EvidenceUpdates2018

15. Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD‐1/PD‐L1 inhibitors

Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD‐1/PD‐L1 inhibitors 30253080 2018 12 07 1759-7714 9 11 2018 Nov Thoracic cancer Thorac Cancer Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors. 1500-1508 10.1111/1759-7714.12877 Immunotherapy is a new paradigm for the treatment of non-small-cell lung cancer (...) January 2016 and February 2018. The mean patient age was 63.9 years, and 72.5% (37/51) were male. Most (92.2%, 47/51) had received previous systemic treatment. The overall response rate was 21.6% (11/51). The response rate was significantly lower in patients with pleural or pericardial metastasis than in patients without pleural or pericardial metastasis (4.3% vs. 35.7%; P = 0.007). Patients with pleural or pericardial metastasis had a significantly higher rate of adverse events of any grade (91.3% vs

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

16. Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial.

Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial. Importance: The appropriate duration of antibiotics for staphylococcal bacteremia is unknown. Objective: To test whether an algorithm that defines treatment duration for staphylococcal bacteremia vs standard of care provides noninferior efficacy without increasing severe adverse events. Design, Setting, and Participants (...) were (1) clinical success, as determined by a blinded adjudication committee and tested for noninferiority within a 15% margin; and (2) serious adverse event rates in the intention-to-treat population, tested for superiority. The prespecified secondary outcome measure, tested for superiority, was antibiotic days among per-protocol patients with simple or uncomplicated bacteremia. Results: Among the 509 patients randomized (mean age, 56.6 [SD, 16.8] years; 226 [44.4%] women), 480 (94.3%) completed

JAMA2018

17. Individual and Joint Effects of Pulse Pressure and Blood Pressure Treatment Intensity on Serious Adverse Events in the SPRINT Trial

Individual and Joint Effects of Pulse Pressure and Blood Pressure Treatment Intensity on Serious Adverse Events in the SPRINT Trial 29940151 2018 08 28 1555-7162 2018 Jun 27 The American journal of medicine Am. J. Med. Individual and Joint Effects of Pulse Pressure and Blood Pressure Treatment Intensity on Serious Adverse Events in the SPRINT Trial. S0002-9343(18)30516-3 10.1016/j.amjmed.2018.05.027 The objective of this study was to determine individual and joint effects of pulse pressure (...) and blood pressure treatment intensity on serious adverse events in the Systolic Blood Pressure Intervention Trial. Pulse pressure was calculated by subtracting diastolic blood pressure from systolic blood pressure. Blood pressure treatment intensity goal was ≤140 mm Hg in the control arm and ≤120 mm Hg in the intensive arm. The primary outcome was a 5-point composite of hypotension, syncope, electrolyte abnormalities, acute renal insufficiency, or injurious falls. In 9361 trial participants

EvidenceUpdates2018

18. [ANZEN]PMDA Alert for Proper Use of Medical Devices: Adverse Events involving the Use of Bioprostheses for Transcatheter Aortic Valve Implantation, posted

[ANZEN]PMDA Alert for Proper Use of Medical Devices: Adverse Events involving the Use of Bioprostheses for Transcatheter Aortic Valve Implantation, posted PMDA Alert for Proper Use of Medical Devices | Pharmaceuticals and Medical Devices Agency Please make JavaScript on and see this site. Navigation of each product type Our recommended contents Navigation of each product type Our recommended contents PMDA Alert for Proper Use of Medical Devices Here begins the text. PMDA Alert for Proper Use (...) ." In the event of inconsistency, the text in Japanese shall prevail. Pmda - Pharmaceuticals and Medical Devices Agency JCN 3010005007409 Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan Copyright (C) Pharmaceuticals and Medical Devices Agency, All Rights Reserved. 000044876 0 PMDA Alert for Proper Use of Medical Devices /english/safety/info-services/devices/0005.html en

Pharmaceuticals and Medical Devices Agency, Japan2018

19. Adverse events

Adverse events Top results for adverse events - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for adverse events The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

20. Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia

Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia 29954814 2018 11 14 2473-9537 2 13 2018 Jul 10 Blood advances Blood Adv Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. 1522-1531 10.1182/bloodadvances.2018019034 In the phase 3 TOWER study, blinatumomab demonstrated an overall survival benefit over standard-of-care chemotherapy (SOC) in adults with relapsed (...) or refractory (r/r) Philadelphia chromosome-negative (Ph - ) B-precursor acute lymphoblastic leukemia (ALL). Nearly all patients in both treatment arms experienced an adverse event (AE), and the incidence rate of serious AEs was higher for blinatumomab. However, as treatment exposure differed between the 2 arms, we conducted an exploratory safety analysis comparing exposure-adjusted event rates (EAERs) of blinatumomab vs SOC. Analyses were conducted for all patients who received therapy (safety population

Blood advances2018 Full Text: Link to full Text with Trip Pro